Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Common Equity (2016 - 2025)

Historic Common Equity for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to $5.4 million.

  • Arcadia Biosciences' Common Equity fell 4708.86% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 4708.86%. This contributed to the annual value of $6.2 million for FY2024, which is 5153.8% down from last year.
  • Latest data reveals that Arcadia Biosciences reported Common Equity of $5.4 million as of Q3 2025, which was down 4708.86% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Arcadia Biosciences' Common Equity peaked at $45.7 million during Q1 2021, and registered a low of $4.5 million during Q2 2025.
  • Its 5-year average for Common Equity is $20.2 million, with a median of $16.8 million in 2023.
  • Per our database at Business Quant, Arcadia Biosciences' Common Equity soared by 27390.98% in 2021 and then crashed by 6126.97% in 2025.
  • Arcadia Biosciences' Common Equity (Quarter) stood at $31.2 million in 2021, then crashed by 32.58% to $21.0 million in 2022, then tumbled by 38.95% to $12.8 million in 2023, then tumbled by 51.54% to $6.2 million in 2024, then decreased by 12.53% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $4.5 million for Q2 2025, and $8.9 million during Q1 2025.